Search

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

84.16 0.27

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

83.86

Max

84.29

Põhinäitajad

By Trading Economics

Sissetulek

7M

-121M

Müük

14M

25M

Aktsiakasum

-1.14

Kasumimarginaal

-481.149

Töötajad

594

EBITDA

-5.8M

-132M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+1.95% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

4.5B

8.9B

Eelmine avamishind

83.89

Eelmine sulgemishind

84.16

Uudiste sentiment

By Acuity

43%

57%

132 / 340 Pingereas Healthcare

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. aug 2026, 23:56 UTC

News

Sweetgreen shares declined in after-market trading as multiple analysts lowered price targets, with UBS and RBC both setting targets at $6.50.

7. aug 2026, 23:46 UTC

News

JetBlue Airways reports wider net loss and updates operating guidance. Shares are lower in after-market trading following the $121.4 million shelf registration.

7. aug 2026, 23:46 UTC

News

Etsy Inc shares are lower in after-market hours following its Q2 results, which showed a double beat but faced revenue challenges from divestments.

7. aug 2026, 23:46 UTC

News

Cogent Communications is trading lower in after-market hours amid a class action lawsuit alleging securities fraud by Pomerantz LLP and ongoing operational challenges.

7. aug 2026, 23:41 UTC

News

ResMed shares declined after-market despite RBC Capital raising its price target to $244 and maintaining a Sector Perform rating.

7. aug 2026, 23:41 UTC

News

Mitek Systems reported an 18% revenue increase in Q3, with shares advancing in after-market hours, despite earlier pulling back from a session high.

7. aug 2026, 23:36 UTC

News

Tripadvisor Inc announced participation in two investor conferences, enhancing engagement with investors. Shares are trading slightly higher in after-market hours.

7. aug 2026, 23:36 UTC

News

Shift4 Payments lowers 2026 outlook, adjusting full-year revenue guidance down by about 200 basis points. Shares are trading lower in after-market hours.

7. aug 2026, 23:36 UTC

News

Epam Systems shares are trading lower in after-market hours following TD Cowen's price target cut to $120, despite earlier gains in the session.

7. aug 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

7. aug 2026, 23:31 UTC

News

Figs Inc reported strong Q2 earnings but is trading lower in after-market hours as Telsey Advisory Group lowered its price target to $16.

7. aug 2026, 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

7. aug 2026, 23:31 UTC

News

Celsius Holdings is under investigation for potential securities law violations following disappointing second-quarter results, with shares trading lower in after-market hours.

7. aug 2026, 23:26 UTC

News

Delta Air Lines is gaining after reporting strong second-quarter results and positive passenger traffic growth projections, with anticipated earnings of $6.63 per share.

7. aug 2026, 23:26 UTC

News

Five9 Inc. reported second-quarter earnings of $0.70 per share and raised full-year revenue guidance to $1.27 billion. Shares are higher in after-market trading.

7. aug 2026, 23:26 UTC

News

UBS raised its price target on Unity Software Inc. to $48, contributing to shares trading higher in after-market hours. Positive sentiment from tech stocks also supported this move.

7. aug 2026, 23:26 UTC

Event
News

Scholar Rock Holding Corp reports FDA review progress for apitegromab, with a decision expected by September 30, 2026. Shares are trading higher in after-market hours.

7. aug 2026, 23:26 UTC

News

Kraft Heinz Co reported second-quarter revenue of $6.26 billion, exceeding expectations. Shares rose in after-market trading amid positive sentiment and broader market strength.

7. aug 2026, 23:26 UTC

News

Leidos Holdings shares are lower in after-market hours after TD Cowen raised the price target to $135 while maintaining a Hold rating.

7. aug 2026, 23:21 UTC

News

MP Materials will participate in Canaccord Genuity's Growth Conference in August 2026. Shares are trading higher in after-market hours following the announcement.

7. aug 2026, 23:21 UTC

News

TD Cowen raised its price target on Akamai Technologies to $140 while maintaining a Hold rating. Shares are higher in after-market trading.

7. aug 2026, 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

7. aug 2026, 23:21 UTC

News

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

7. aug 2026, 23:16 UTC

News

Hawaiian Electric Industries reported Q2 revenues of $939.70 million, but adjusted EPS of $0.13 missed estimates by $0.06. Shares are trading roughly flat in after-hours.

7. aug 2026, 23:16 UTC

News

10X Genomics Inc shares are lower in after-market trading amid a sector decline. Citigroup raised its price target to $50 while maintaining a Neutral rating.

7. aug 2026, 23:11 UTC

News

Ashland Inc. is exploring a potential sale amid takeover interest, while announcing a quarterly cash dividend of $0.42 per share. Shares lower in after-market trading.

7. aug 2026, 23:06 UTC

News

Baker Hughes reported a stable U.S. rig count of 588, with oil rigs rising to 454 and gas rigs declining to 124. Shares were little changed in after-market trading.

7. aug 2026, 23:06 UTC

News

Kimberly-Clark Corp shares are lower in after-market trading, reflecting ongoing challenges with revenue and margins amid rising input costs and competition.

7. aug 2026, 23:06 UTC

News

Photronics Inc shares are lower in after-market trading following a class action lawsuit alleging misleading statements about its product pipeline and demand stability.

7. aug 2026, 23:06 UTC

News

Morgan Stanley shares are lower after-market, reflecting a slight decline. The movement follows the bank's $400 million Bitcoin purchases amid uncertain market conditions.

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

1.95% tõus

12 kuu keskmine prognoos

Keskmine 85.56 USD  1.95%

Kõrge 95 USD

Madal 80 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

2

Osta

12

Hoia

0

Müü

Sentiment

By Acuity

132 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat